Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 studyRenato Bassan, Robin Foà, Orietta Spinelli et al.|Blood|2025Cited by 37
Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 TrialMarco Beldinanzi, Sabina Chiaretti, Vittorio Bellomarino et al.|Blood|2024Cited by 0